---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Positive airway pressure therapy"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Positive airway pressure therapy. Topics: VA/DoD guideline: evidence cutoff date for the 2025 recommendations; VA/DoD guideline: mandibular advancement devices, PAP, or surgical referral (strong for); VA/DoD guideline algorithm: PAP as first-line therapy for severe OSA; VA/DoD guideline: auto-titrating over fixed CPAP at initiation (weak for); 17 further topics. 21 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/positive-airway-pressure-therapy"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Positive airway pressure therapy

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Positive Airway Pressure Therapy

<a id="topic-2.2.2.1.1-1"></a>

### VA/DoD guideline: evidence cutoff date for the 2025 recommendations

> “This CPG is based on published clinical evidence and related information available through March 31, 2024.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-2"></a>

### VA/DoD guideline: mandibular advancement devices, PAP, or surgical referral (strong for)

> “17. For treatment of obstructive sleep apnea, we recommend one or more of the following evidence-based therapies, depending on patient values and characteristics:”
> “Thus, based on the recognized risk of catastrophic harms from not providing effective treatment for OSA, the Work Group decided upon a Strong for recommendation.”
> “Positive airway pressure (PAP) therapy in the form of auto-PAP (APAP), continuous PAP (CPAP) and bilevel PAP (BPAP) is considered the first line of therapy.”
> “The updated guideline strongly recommends treatment for OSA but does not limit the therapy to PAP.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-3"></a>

### VA/DoD guideline algorithm: PAP as first-line therapy for severe OSA

> “Prescribe PAP as first line therapy for patient with severe OSA (i.e., AHI >30 events per hour)”
> “Prescribe PAP or MAD for other OSA severity (i.e., AHI 5 to <30 events per hour), based on clinical evaluation, comorbidities, and patient preference.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-4"></a>

### VA/DoD guideline: auto-titrating over fixed CPAP at initiation (weak for)

> “19. For treatment of newly diagnosed obstructive sleep apnea, we suggest initiating auto-titrating over fixed continuous positive airway pressure to facilitate usage. Weak for”
> “Although usage (hours/night) was increased with APAP, there was no significant difference observed in the number of patients adhering ≥4 hours/night between APAP and fixed CPAP.”
> “The Work Group’s confidence in the quality of the evidence for this recommendation is low.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-5"></a>

### VA/DoD guideline: educational, behavioral, and supportive interventions to improve PAP usage (weak for)

> “26. For treatment of obstructive sleep apnea in patients who are prescribed positive airway pressure therapy, we suggest the use of in-person or telehealth educational, behavioral, and supportive interventions to improve PAP usage. Weak for”
> “Behavioral interventions showed the most significance in hourly usage with an increase in average PAP usage per night by 1.31 hours per night (95% CI: 0.95 to 1.66) when compared to usual care.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-6"></a>

### VA/DoD guideline: PAP effects on symptoms, cardiovascular outcomes, and side effects

> “As a measure of mean disease alleviation, the studies showed that CPAP use significantly reduced OSA symptoms including snoring, witnessed apnea, choking during sleep, excessive daytime sleepiness as measured by ESS, anxiety, depression, insomnia, and functionality.”
> “The recent evidence did not show improvement in cardiovascular outcomes (CV mortality, stroke, MI, incident atrial fibrillation, and composite CV outcomes), and neurocognitive tests.”
> “As far as side effects, PAP has been associated with nasal congestion, oronasal dryness, mask discomfort, and nocturnal awakenings.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-7"></a>

### AASM guideline: PAP for excessive sleepiness (strong), impaired sleep-related quality of life (conditional), and comorbid hypertension (conditional)

> “Recommendation 1: We recommend that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with excessive sleepiness. (STRONG)”
> “The TF identified 38 randomized controlled trials (RCTs) that assessed the efficacy of PAP to reduce excessive sleepiness.”
> “Recommendation 2: We suggest that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with impaired sleep-related quality of life. (CONDITIONAL)”
> “Recommendation 3: We suggest that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with comorbid hypertension. (CONDITIONAL)”
> “This clinical practice guideline reflects the state of knowledge at the time of publication and will be reviewed and updated as new information becomes available.”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.1.1-8"></a>

### AASM guideline: PAP initiation, modality, and adherence interventions

> “Recommendation 4: We recommend positive airway pressure therapy be initiated using either APAP at home or in-laboratory PAP titration in adults with OSA and no significant comorbidities. (STRONG)”
> “Recommendation 5: We recommend that clinicians use either APAP or CPAP for ongoing treatment of OSA in adults. (STRONG)”
> “Recommendation 6: We suggest that clinicians use CPAP or APAP over BPAP in the routine treatment of OSA in adults. (CONDITIONAL)”
> “Recommendation 7: We recommend that educational interventions be given prior to initiation of PAP therapy in adults with OSA. (STRONG)”
> “Recommendation 9: We suggest that clinicians use telemonitoring-guided interventions during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.1.1-9"></a>

### AASM guideline: no recommendation on PAP to reduce cardiovascular events in non-sleepy adults

> “There is insufficient and inconclusive evidence to either recommend or withhold PAP to treat non-sleepy adults with OSA as a means to reduce cardiovascular events or mortality.”
> “Meta-analyses of observational studies suggested a reduction in CV events and mortality with PAP therapy. In contrast, meta-analyses of randomized controlled trials demonstrated no clinically significant improvements in CV events or mortality.”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.1.1-10"></a>

### ACP guideline: CPAP as initial therapy (strong recommendation, moderate-quality evidence)

> “This guideline is based on published literature from 1966 to September 2010 that was identified by using MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews.”
> “RECOMMENDATION 2: ACP recommends continuous positive airway pressure treatment as initial therapy for patients diagnosed with OSA. (Grade: strong recommendation; moderate-quality evidence)”

Source: [Qaseem et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24061345/)

<a id="topic-2.2.2.1.1-11"></a>

### SAVE: CPAP and cardiovascular events in OSA with established cardiovascular disease, OSA defined by a 4% oxygen desaturation index of at least 12

> “The diagnosis of moderate-to-severe obstructive sleep apnea, which was defined as an oxygen desaturation index (the number of times per hour during the oximetry recording that the blood oxygen saturation level drops by ≥4 percentage points from baseline) of at least 12, was established with the use of a home sleep-study screening device (ApneaLink, ResMed) and was confirmed by review of the data at a central core sleep laboratory.”
> “In the CPAP group, the mean duration of adherence to CPAP therapy was 3.3 hours per night, and the mean apnea–hypopnea index (the number of apnea or hypopnea events per hour of recording) decreased from 29.0 events per hour at baseline to 3.7 events per hour during follow-up.”
> “After a mean follow-up of 3.7 years, a primary end-point event had occurred in 229 participants in the CPAP group (17.0%) and in 207 participants in the usual-care group (15.4%) (hazard ratio with CPAP, 1.10; 95% confidence interval, 0.91 to 1.32; P=0.34).”
> “CPAP significantly reduced snoring and daytime sleepiness and improved health-related quality of life and mood.”
> “Therapy with CPAP plus usual care, as compared with usual care alone, did not prevent cardiovascular events in patients with moderate-to-severe obstructive sleep apnea and established cardiovascular disease.”

Source: [McEvoy et al. (2016)](https://www.nejm.org/doi/full/10.1056/NEJMoa1606599)

<a id="topic-2.2.2.1.1-12"></a>

### ISAACC: CPAP and cardiovascular events after acute coronary syndrome in non-sleepy participants

> “The prevalence of cardiovascular events was similar in the CPAP and UC groups (98 events [16%] vs 108 events [17%]; hazard ratio [HR] 0·89 [95% CI 0·68-1·17]; p=0·40) during follow-up.”
> “Mean time of adherence to CPAP treatment was 2·78 h/night (SD 2·73).”
> “Among non-sleepy patients with ACS, the presence of OSA was not associated with an increased prevalence of cardiovascular events and treatment with CPAP did not significantly reduce this prevalence.”

Source: [Sánchez-de-la-Torre et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31839558/)

<a id="topic-2.2.2.1.1-13"></a>

### RICCADSA: CPAP in coronary artery disease with non-sleepy OSA, AHI of at least 15 per hour, hypopnea scoring rule not stated in the abstract

> “Consecutive patients with newly revascularized CAD and OSA (apnea-hypopnea index ≥15/h) without daytime sleepiness (Epworth Sleepiness Scale score <10) were randomized to auto-titrating CPAP (n = 122) or no positive airway pressure (n = 122).”
> “The incidence of the primary endpoint did not differ significantly in patients who did versus did not receive CPAP (18.1% vs. 22.1%; hazard ratio, 0.80; 95% confidence interval, 0.46-1.41; P = 0.449).”
> “Adjusted on-treatment analysis showed a significant cardiovascular risk reduction in those who used CPAP for ≥4 versus <4 hours per night or did not receive treatment (hazard ratio, 0.29; 95% confidence interval, 0.10-0.86; P = 0.026).”

Source: [Peker et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26914592/)

<a id="topic-2.2.2.1.1-14"></a>

### CPAP and incident hypertension or cardiovascular events in non-sleepy OSA, AHI of at least 20 per hour, hypopnea scoring rule not stated in the abstract

> “Between May 2004 and May 2006, 725 consecutive patients were enrolled who had an apnea-hypopnea index of 20 h(-1) or greater and an Epworth Sleepiness Scale score of 10 or less (scores range from 0-24, with values <10 suggesting no daytime sleepiness).”
> “The incidence density ratio was 0.83 (95% CI, 0.63-1.1; P = .20).”
> “In patients with OSA without daytime sleepiness, the prescription of CPAP compared with usual care did not result in a statistically significant reduction in the incidence of hypertension or cardiovascular events. However, the study may have had limited power to detect a significant difference.”

Source: [Barbé et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22618923/)

<a id="topic-2.2.2.1.1-15"></a>

### Individual participant data meta-analysis of SAVE, ISAACC, and RICCADSA: intention-to-treat and adherent CPAP use

> “The main outcome was defined as the first MACCE, which was similar for the CPAP and no CPAP groups (hazard ratio, 1.01 [95% CI, 0.87-1.17]). However, an on-treatment analysis by marginal structural model revealed a reduced risk of MACCEs associated with good adherence to CPAP (hazard ratio, 0.69 [95% CI, 0.52-0.92]).”
> “A total of 4186 individual participants were evaluated (82.1% men; mean [SD] body mass index, 28.9 [4.5]; mean [SD] age, 61.2 [8.7] years; mean [SD] apnea-hypopnea index, 31.2 [17] events per hour; 71% with hypertension; 50.1% receiving CPAP [mean {SD} adherence, 3.1 {2.4} hours per day]; 49.9% not receiving CPAP [usual care], mean [SD] follow-up, 3.25 [1.8] years).”

Source: [Sánchez-de-la-Torre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10548300/)

<a id="topic-2.2.2.1.1-16"></a>

### Meta-analysis of randomized trials: PAP and cardiovascular events or death in sleep apnea

> “The use of PAP, compared with no treatment or sham, was not associated with reduced risks of cardiovascular outcomes or death for patients with sleep apnea. Although there are other benefits of treatment with PAP for sleep apnea, these findings do not support treatment with PAP with a goal of prevention of these outcomes.”
> “Mean or median adherence to the intervention ranged between 1.4 hours per day and 6.6 hours per day.”

Source: [Yu et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5541330/)

<a id="topic-2.2.2.1.1-17"></a>

### Adherence: nonadherence range across studies using a 4-hour nightly threshold

> “When adherence is defined as greater than 4 hours of nightly use, 46 to 83% of patients with obstructive sleep apnea have been reported to be nonadherent to treatment.”

Source: [Weaver and Grunstein (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2645251/)

<a id="topic-2.2.2.1.1-18"></a>

### Adherence: CPAP nonadherence pooled across 20 years of trials, relative to a 7-hour night

> “The overall CPAP non-adherence rate based on a 7-h/night sleep time that was reported in studies conducted over the twenty year time frame was 34.1 %. There was no significant improvement over the time frame.”

Source: [Rotenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4992257/)

<a id="topic-2.2.2.1.1-19"></a>

### Adherence: 90-day adherence by the Medicare definition in a device manufacturer’s cloud database

> “We assessed de-identified data from a large cloud database of positive airway pressure (PAP) users to examine adherence to therapy during the period 1-Oct-2014 to 31-Oct-2017.”
> “All Air10 platform PAP devices (ResMed Inc., San Diego, USA) have an on-board mobile communications chip which connects to the secure cloud infrastructure automatically.”
> “ResMed Corp, USA funded the study and their employees (JA, AB, CMN) contributed to the design and conduct of the study, analysis, and interpretation of the data and preparation of the manuscript for publication.”
> “The primary outcome was adherence, which was defined using the US Center for Medicare and Medicaid Services (CMS) definition (≥4 hours’ PAP use on 70% of nights in a consecutive 30-day period in the first 90 days of therapy).”
> “The observed 90-day PAP adherence rate using the CMS definition was 75%.”
> “Prior studies suggest that up to 24% of patients may not fulfill their PAP prescription [14] and a proportion of patients may not even turn on their PAP machine.”

Source: [Cistulli et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6589354/)

<a id="topic-2.2.2.1.1-20"></a>

### Termination: CPAP termination at 1, 2, and 3 years in French national claims

> “Therapy termination was defined as cessation of CPAP reimbursements.”
> “A total of 480,000 patients were included (mean age 59.3 ± 13.6 years, 65.4% male).”
> “Overall CPAP termination rates after 1, 2 and 3 years were 23.1, 37.1 and 47.7%, respectively.”
> “Therapy termination rates were highest in younger or older patients with ≥1 comorbidity.”

Source: [Pépin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7957656/)

<a id="topic-2.2.2.1.1-21"></a>

### Persistence: five-year PAP persistence under telemonitoring and pay-for-performance in France

> “A total of 84,550 patients (63.7% men, mean age 58.5 years, 53.6% with obesity, mean apnea-hypopnea index 40 events/h) were included; 95.7% used telemonitoring.”
> “PAP therapy persistence was 83.5% at 1 year, 68.4% at 3 years and 60.5% at 5 years.”
> “Main documented reasons for stopping PAP were issues with PAP treatment (54.9%), changes in treatment needs (9.3%) and death (7.0%).”
> “However, solutions are needed for patients who have PAP-related issues and to further reduce the therapy termination rate.”

Source: [Baillieul et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43033026/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
